UNMIRI Launches Precision Oncology API Platform for Design Partners

Details

The UNMIRI platform aims to solve the problem of fragmented genomic reporting by integrating diverse Next-Generation Sequencing (NGS) reports from multiple labs (e.g., Foundation Medicine, Tempus). It normalizes reports from nine or more vendors into a single FHIR R4 Genomics representation. Key features include HGVS-normalized variants and biomarkers like TMB, MSI, and PD-L1. The platform offers genomics-aware decision support, providing drug-variant pharmacogenomics and therapy options graded by public tiers (AMP/ASCO/CAP 2017). Crucially, UNMIRI emphasizes verifiability: it resolves variant identity using a typed Neo4j knowledge graph before any decision step, ensuring accuracy. All recommendations trace back to public, citable sources such as CIViC, ClinVar, and ClinicalTrials.gov. The system operates on HIPAA-ready AWS infrastructure and is designed to meet FDA Non-Device Clinical Decision Support criteria, providing structured inputs and a fully cited basis for clinicians.